Breaking News on Immunovative, Inc. as it gets a very important patent. This patent protects IMUN’s lead drug candidate called AlloStim™. AlloStim™ is essentially a method for preparing cells for patient treatment. Specifically this patent covers the infusion of immune T-cells that come from a donor. The press release below has more details. The Company’s web site has a great page on it as well. See the link below to go to that page.
*** Visit StockGuru.com ***
*** The StockGuru Spotlight Success Record ***
*** Get StockGuru Email Alerts ***
*** Read More About IMUN: http://stockguru.com//tag/imum ***
Read the details below.
Here is the headline:
About Immunovative Therapies, Ltd.:
Immunovative Therapies, Ltd. is an Israeli biopharmaceutical company that was founded in May 2004 with financial support from the Israeli Office of the Chief Scientist. ITL is a graduate of the Misgav Venture Accelerator, a member of the world-renowned Israeli technological incubator program. The company was the Misgav Venture Accelerator’s candidate for the prize for the outstanding incubator project of 2006, awarded by the Office of the Chief Scientist. ITL specializes in the development of novel immunotherapy drug products that incorporate living immune cells as the active ingredients for treatment of cancer and infectious disease.
Please visit ITL’s website at: www.immunovative.co.il
Here is the page on AlloStim™: http://www.immunovative.co.il/alloStim.php